AOD-9604 vs Pramlintide
A side-by-side research comparison of AOD-9604 and Pramlintide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AOD-9604 | Pramlintide |
|---|---|---|
| Full name | Advanced Obesity Drug Fragment 176-191 (Modified) | Pramlintide (Symlin) |
| Category | Weight Management | Weight Management |
| Status | Research compound | FDA Approved |
| Mechanism | Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling. | Mimics amylin by activating amylin receptors, which slows gastric emptying, suppresses inappropriate glucagon secretion after meals, and increases satiety - complementing insulin's effects. |
| Molecular weight | 1815.08 Da | 3949.4 Da |
| Half-life | ~2-3 hours | ~48 minutes |
| Bioavailability | ~90% subcutaneous | Subcutaneous injection |
| Typical dose | 300 mcg | 15-120 mcg before meals |
| Frequency | Daily (morning, fasted) | Before major meals |
| Route | Subcutaneous injection | Subcutaneous injection |
AOD-9604 reported benefits
- Fat loss without muscle wasting
- No effect on blood sugar
- Cartilage repair properties
- No HGH-related side effects
Pramlintide reported benefits
- Appetite suppression and satiety
- Slows gastric emptying
- Improves post-meal glucose control
- Modest weight loss
Related comparisons
Research and educational reference only. Not medical advice.